Showing 37–48 of 140 results

Show sidebar
Show 9 12 18 24
Compare

Isturisa (osilodrostat)

£1,223.26 – £6,000.00
Isturisa (osilodrostat) is a medication used for the treatment of adult patients with Cushing’s syndrome or for adults with Cushing’s disease who are not candidates for surgery, or who did not respond to prior surgery.
Add to wishlist
Select options
Quick view
Compare

Jyseleca (filgotinib)

£1,741.89
Jyseleca (filgotinib) is a medication used in adults to treat moderate to severe rheumatoid arthritis.
Add to wishlist
Select options
Quick view
Compare

Kaftrio* (elexacaftor/tezacaftor/ivacaftor)

£14,950.00 – £17,057.00
Kaftrio (elexacaftor/tezacaftor/ivacaftor)* is a medication used in combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Add to wishlist
Select options
Quick view
Compare

Kalydeco* (ivacaftor)

£8,842.12 – £17,868.02
Kalydeco (ivacaftor)* is a medicine indicated for the treatment of patients with cystic fibrosis (CF) aged 4 months and older who have at least one mutation in their CF gene that is responsive to Kalydeco.
Add to wishlist
Select options
Quick view
Compare

Kerendia (finerenone)

£550.00 – £1,500.00
Kerendia (finerenone) is a prescription medicine used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, nonfatal heart attacks and hospitalization for heart failure in patients with chronic kidney disease associated with type 2 diabetes...
Add to wishlist
Select options
Quick view
Compare

Ketas (ibudilast)

£442.13
Ketas (ibudilast) is a medication used for the treatment of bronchial asthma and for cerebrovascular (brain and blood vessel) disorders. Ibudilast has received orphan drug status for the treatment of patients affected by amyotrophic lateral sclerosis (ALS) by EMA and FDA.
Add to wishlist
Select options
Quick view
Compare

Lagevrio (molnupiravir)

Lagevrio (molnupiravir) is a prescription medicine used to treat mild-to-moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. This medicine has been given ‘conditional approval’. This means that there is more evidence to come about its efficacy.
Add to wishlist
Price available on request
Quick view
Compare

Leqvio (inclisiran)

£1,850.00
Leqvio (inclisiran) is a medication used to reduce cholesterol levels in adults with primary hypercholesterolaemia or mixed dyslipidaemia.
Add to wishlist
Select options
Quick view
Compare

Libtayo (cemiplimab)

£8,328.00
Libtayo (cemiplimab) is a medication used for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), advanced basal cell carcinoma (BCC) and advanced non-small cell lung cancer (NSCLC).
Add to wishlist
Select options
Quick view
Compare

Livdelzi (seladelpar)

Livdelzi (seladelpar) is a prescription medicine for the treatment of adults with primary biliary cholangitis (PBC). It can be used in combination with ursodeoxycholic acid (UDCA) for patients who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA. Livdelzi (seladelpar) is currently only approved in the USA.
Add to wishlist
Price available on request
Quick view
Compare

Livmarli (maralixibat)

£22,700.00
Livmarli (maralixibat) is an oral solution to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.
Add to wishlist
Add to cart
Quick view
Compare

Lucaftor (lumacaftor/ivacaftor)

£3,730.82
Lucaftor (lumacaftor/ivacaftor) is a medicine indicated for the treatment of cystic fibrosis (CF) in patients 12 years and older who have two copies of the F508del mutation (F508del/F508del) in the CFTR gene.
Add to wishlist
Select options
Quick view